A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Blondonnet, Raiko ^a,b   Constantin, Jean Michel ^a,b   Sapin, Vincent ^a,b   Jabaudon, Matthieu ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA 2 MACROGLOBULIN; ANGIOPOIETIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CLARA CELL PROTEIN; DESMOSINE; ELASTIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMININ; LUNG SURFACTANT; MATRIX METALLOPROTEINASE; MUCIN 1; SELECTIN; THROMBIN; THROMBOMODULIN; TROPONIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; CELL PROLIFERATION; CLARA CELL; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; EXTRACELLULAR MATRIX; FIBROBLAST; HIGH RISK PATIENT; HUMAN; LUNG ALVEOLUS CELL TYPE 1; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; OUTCOME ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; COMPUTER ASSISTED DIAGNOSIS; METABOLISM; PROGNOSIS;

BIOMARKERS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84959196247     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/3501373     Document Type: Review

References (217)

1. V.M.Ranieri, G. D. Rubenfeld, P. T.Thompsonet al., "Acute respiratory distress syndrome: the Berlin definition," The Journal of the American Medical Association, vol. 307, no. 23, pp. 2526-2533, 2012.
2. L. B. Ware and M. A. Matthay, "The acute respiratory distress syndrome," The New England Journal of Medicine, vol. 342, no. 18, pp. 1334-1349, 2000.
3. C. Brun-Buisson, C. Minelli, G. Bertolini et al., "Epidemiology and outcome of acute lung injury in European intensive care units," Intensive Care Medicine, vol. 30, no. 1, pp. 51-61, 2004.
4. G. D. Rubenfeld, E. Caldwell, E. Peabody et al., "Incidence and outcomes of acute lung injury," The New England Journal of Medicine, vol. 353, no. 16, pp. 1685-1693, 2005.
5. D. W. Dowdy, M. P. Eid, C. R. Dennison et al., "Quality of life after acute respiratory distress syndrome: a meta-analysis," Intensive Care Medicine, vol. 32, no. 8, pp. 1115-1124, 2006.
6. C. S. Calfee,M.D. Eisner, L. B. Ware et al., "Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders," Critical Care Medicine, vol. 35, no. 10, pp. 2243-2250, 2007.
7. C. S. Calfee,D.R. Janz, G. R. Bernard et al., "Distinct molecular phenotypes of direct versus indirect ARDS in single and multicenter studies," Chest, vol. 147, no. 6, pp. 1539-1548, 2015.
8. P. Tejera, N. J. Meyer, F. Chen et al., "Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin," Journal of Medical Genetics, vol. 49, no. 11, pp. 671-680, 2012.
9. M. A. Matthay, G. A. Zimmerman, C. Esmon et al., "Future research directions in acute lung injury: summary of a National Heart, Lung, Blood Institute Working Group," American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 7, pp. 1027-1035, 2003.
10. J. P. Reilly, S. Bellamy, M. G. S. Shashaty et al., "Heterogeneous phenotypes of acute respiratory distress syndrome after major trauma," Annals of the American Thoracic Society, vol. 11, no. 5, pp. 728-736, 2014.
11. L. Puybasset, P. Cluzel,N. Chao et al., "A computed tomography scan assessment of regional lung volume in acute lung injury," American Journal of Respiratory and Critical CareMedicine, vol. 158, no. 5, pp. 1644-1655, 1998.
12. J.-M. Constantin, S. Grasso,G. Chanques et al., "Lung morphology predicts response to recruitmentmaneuver in patients with acute respiratory distress syndrome," Critical Care Medicine, vol. 38, no. 4, pp. 1108-1117, 2010.
13. C. S. Calfee, K. Delucchi, P. E. Parsons, B. T. Thompson, L. B. Ware, M. A. Matthay, "Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials,"The Lancet Respiratory Medicine, vol. 2, no. 8, pp. 611-620, 2014.
14. R.Marshall, G. Bellingan, G. Laurent, "The acute respiratory distress syndrome: fibrosis in the fast lane," Thorax, vol. 53, no. 10, pp. 815-817, 1998.
15. R. B. Henderson, J. A. R. Hobbs, M. Mathies, N. Hogg, "Rapid recruitment of inflammatory monocytes is independent of neutrophil migration," Blood, vol. 102, no. 1, pp. 328-335, 2003.
16. H. M.Marriott andD. H.Dockrell, "Therole of themacrophage in lung disease mediated by bacteria," Experimental Lung Research, vol. 33, no. 10, pp. 493-505, 2007.
17. L. J. M. Cross and M. A. Matthay, "Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury," Critical Care Clinics, vol. 27, no. 2, pp. 355-377, 2011.
18. H. K. Gaggin and J. L. Januzzi, "Biomarkers and diagnostics in heart failure," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1832, no. 12, pp. 2442-2450, 2013.
19. E. Christenson and R. H. Christenson, "The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome," Annals of Laboratory Medicine, vol. 33, no. 5, pp. 309-318, 2013.
20. L. B. Ware, T. Koyama, Z. Zhao et al., "Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome," Critical Care, vol. 17, no. 5, article R253, 2013.
21. M. A. Matthay, L. B. Ware, G. A. Zimmerman, "The acute respiratory distress syndrome," The Journal of Clinical Investigation, vol. 122, no. 8, pp. 2731-2740, 2012.
22. M. Shirasawa, N. Fujiwara, S. Hirabayashi et al., "Receptor for advanced glycation end-products is a marker of type I lung alveolar cells," Genes to Cells, vol. 9, no. 2, pp. 165-174, 2004.
23. M. Neeper, A. M. Schmidt, J. Brett et al., "Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins," The Journal of Biological Chemistry, vol. 267, no. 21, pp. 14998-15004, 1992.
24. M. Jabaudon, E. Futier, L. Roszyk, V. Sapin, B. Pereira, J. Constantin, "Association between intraoperative ventilator settings and plasma levels of soluble receptor for advanced glycation end-products in patients without pre-existing lung injury," Respirology, vol. 20, no. 7, pp. 1131-1138, 2015.
25. L. G. Dobbs, R. F. Gonzalez, L. Allen, D. K. Froh, "HTI56, an integral membrane protein specific to human alveolar type I cells," Journal of Histochemistry & Cytochemistry, vol. 47, pp. 129-137, 1999.
26. L. G. Dobbs, M. C. Williams, R. Gonzalez, "Monoclonal antibodies specific to apical surfaces of rat alveolar type I cells bind to surfaces of cultured, but not freshly isolated, type II cells,"Molecular Cell Research, vol. 970, no. 2, pp. 146-156, 1988.
27. I. W. Cheng, L. B. Ware, K. E. Greene, T. J. Nuckton, M. D. Eisner, M. A. Matthay, "Prognostic value of surfactant proteins A and D in patients with acute lung injury," Critical Care Medicine, vol. 31, no. 1, pp. 20-27, 2003.
28. A. Agrawal, H. Zhuo, S. Brady et al., "Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 303, no. 8, pp. L634-L639, 2012.
29. H. Sato, M. E. J. Callister, S. Mumby et al., "KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome," European Respiratory Journal, vol. 23, no. 1, pp. 142-145, 2004.
30. R. M. Determann, A. A. N. M. Royakkers, J. J. Haitsma et al., "Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients," BMC Pulmonary Medicine, vol. 10, article 6, 2010.
31. F. Broeckaert and A. Bernard, "Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker," Clinical and Experimental Allergy, vol. 30, no. 4, pp. 469-475, 2000.
32. R. Cartin-Ceba, R. D. Hubmayr, R. Qin et al., "Predictive value of plasma biomarkers for mortality and organ failure development in patients with acute respiratory distress syndrome," Journal of Critical Care, vol. 30, no. 1, pp. 219.e1-219.e7, 2015.
33. L. Eklund and P. Saharinen, "Angiopoietin signaling in the vasculature," ExperimentalCell Research, vol. 319, no.9,pp. 1271-1280, 2013.
34. C. S. Calfee, D. Gallagher, J. Abbott, B. T. Thompson, M. A. Matthay, "Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance," Critical Care Medicine, vol. 40, no. 6, pp. 1731-1737, 2012.
35. M. L. Dustin, R. Rothlein, A. K. Bhan, C. A. Dinarello, T. A. Springer, "Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, function of a natural adherence molecule (ICAM-1)," The Journal of Immunology, vol. 137, no. 1, pp. 245-254, 1986.
36. R. P.McEver, "Selectins: lectins that initiate cell adhesion under flow," Current Opinion in Cell Biology, vol. 14, no. 5, pp. 581-586, 2002.
37. D. Osaka, Y. Shibata, K. Kanouchi et al., "Soluble endothelial selectin in acute lung injury complicated by severe pneumonia," International Journal of Medical Sciences, vol. 8, no. 4, pp. 302-308, 2011.
38. M. Shibuya, "Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases," Journal of Biochemistry, vol. 153, no. 1, pp. 13-19, 2013.
39. L. B.Ware, R. J. Kaner, R. G. Crystal et al., "VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedama," European Respiratory Journal, vol. 26, no. 1, pp. 101-105, 2005.
40. L. B.Ware, M. D. Eisner, B. T. Thompson, P. E. Parsons, M. A.Matthay, "Significance of vonWillebrand factor in septic and nonseptic patients with acute lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 7, pp. 766-772, 2004.
41. A. J. Reininger, "Function of von Willebrand factor in haemostasis and thrombosis," Haemophilia, vol. 14, supplement 5, pp. 11-26, 2008.
42. M. S. Bajaj and S. M. Tricomi, "Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, thrombomodulin do not predict the development of acute respiratory distress syndrome," Intensive Care Medicine, vol. 25, no. 11, pp. 1259-1266, 1999.
43. J.Tzu and M. P.Marinkovich, "Bridging structure with function: structural, regulatory, developmental role of laminins," International Journal of Biochemistry and Cell Biology, vol. 40, no. 2, pp. 199-214, 2008.
44. K. Torii, K.-I. Iida, Y. Miyazaki et al., "Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome," American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 1, pp. 43-46, 1997.
45. E. G. Cleary and M. A. Gibson, "Elastic tissue, elastin and elastin associated microfibrils," in Extracellular Matrix, vol. 2, pp. 95-140, Harwood Academic Publishers, Amsterdam, The Netherlands, 1996.
46. D. E.McClintock, B. Starcher, M. D. Eisner et al., "Higher urine desmosine levels are associated with mortality in patients with acute lung injury," The American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 291, no.4,pp. L566-L571, 2006.
47. J. Hästbacka, R. Linko, T. Tervahartiala et al., "Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality," Anesthesia & Analgesia, vol. 118, no. 4, pp. 790-798, 2014.
48. A. H. Hergrueter, K. Nguyen, C. A. Owen, "Matrix metalloproteinases: all the RAGE in the acute respiratory distress syndrome,"The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 300, no. 4, pp. L512-L515, 2011.
49. N. Yamakawa, T. Uchida, M. A. Matthay, K. Makita, "Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 300, no. 4, pp. L516-L525, 2011.
50. T. Strowig, J. Henao-Mejia, E. Elinav, R. Flavell, "Inflammasomes in health and disease," Nature, vol. 481, no. 7381, pp. 278-286, 2012.
51. H.Makabe,M. Kojika, G. Takahashi et al., "Interleukin-18 levels reflect the long-term prognosis of acute lung injury and acute respiratory distress syndrome," Journal ofAnesthesia, vol. 26,no. 5, pp. 658-663, 2012.
52. J. Cohen, "The immunopathogenesis of sepsis," Nature, vol. 420, no. 6917, pp. 885-891, 2002.
53. D. Bouros, M. G. Alexandrakis, K. M. Antoniou et al., "The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome," BMC PulmonaryMedicine, vol. 4, article 6, 2004.
54. P. E. Parsons, M. A. Matthay, L. B. Ware, M. D. Eisner, "Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury,"The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 288, no. 3, pp. L426-L431, 2005.
55. G.U.Meduri, S. Headley, G. Kohler et al., "Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1 and IL-6 levels are consistent and efficient predictors of outcome over time," Chest, vol. 107, no. 4, pp. 1062-1073, 1995.
56. P. E. Parsons, M. Moss, J. L. Vannice, E. E. Moore, F. A. Moore, J. E. Repine, "Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients," American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 4, pp. 1469-1473, 1997.
57. M. A. Kovach, K. A. Stringer, R. Bunting et al., "Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patientswith acute respiratory distress syndrome," Respiratory Research, vol. 16, article 29, 2015.
58. R. G. Brower, P. N. Lanken, N. MacIntyre et al., "Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome,"The New England Journal of Medicine, vol. 351, no. 4, pp. 327-336, 2004.
59. P. E. Parsons, M. D. Eisner, B. T.Thompson et al., "Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury," Critical Care Medicine, vol. 33, no. 1, pp. 1-6, 2005.
60. D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, A. O'Garra, "IL-10 inhibits cytokine production by activated macrophages," Journal of Immunology, vol. 147, no. 11, pp. 3815-3822, 1991.
61. L. Armstrong and A. B. Millar, "Relative production of tumour necrosis factor and interleukin 10 in adult respiratory distress syndrome," Thorax, vol. 52, no. 5, pp. 442-446, 1997.
62. M. J. Cohen, K. Brohi, C. S. Calfee et al., "Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion," Critical Care, vol. 13, no. 6, article R174, 2009.
63. T.Nakamura, E. Sato,N.Fujiwara, Y. Kawagoe, S.Maeda,S.-I. Yamagishi, "Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome," Clinical Biochemistry, vol. 44, no. 8-9, pp. 601-604, 2011.
64. T. R.Martin, G. D. Rubenfeld, J. T. Ruzinski et al., "Relationship between soluble CD14, lipopolysaccharide binding protein, the alveolar inflammatory response in patients with acute respiratory distress syndrome," American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 3, pp. 937-944, 1997.
65. J. Villar, L. Pérez-Méndez, E. Espinosa et al., "Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis," PLoS ONE, vol. 4, no. 8, Article ID e6818, 2009.
66. C. Sittipunt, K. P. Steinberg, J. T. Ruzinski et al., "Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome,"AmericanJournal of Respiratory andCritical Care Medicine, vol. 163, no. 2, pp. 503-510, 2001.
67. L. B.Ware, J. A. Magarik, N. Wickersham et al., "Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis," Critical Care, vol. 17, article R10, 2013.
68. E. K. Bajwa, U. A. Khan, J. L. Januzzi, M. N. Gong, B. T. Thompson, D. C. Christiani, "Plasma C-reactive protein levels are associated with improved outcome in ARDS," Chest, vol. 136, no. 2, pp. 471-480, 2009.
69. S. H. Hoeboer, H. M. Oudemans-van Straaten, A. B. J. Groeneveld, "Albumin rather than C-reactive protein may be valuable in predicting and monitoring the severity and course of acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new onset fever," BMC Pulmonary Medicine, vol. 15, article 22, 2015.
70. I. R. Doyle, C. Hermans, A. Bernard, T. E. Nicholas, A. D. Bersten, "Clearance of clara cell secretory protein 16 (CC16) and surfactant proteins A and B from blood in acute respiratory failure," American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 5, pp. 1528-1535, 1998.
71. L. B. Ware, J. A. Bastarache, L. Wang, "Coagulation and fibrinolysis in human acute lung injury-new therapeutic targets" Keio Journal of Medicine, vol. 54, no. 3, pp. 142-149, 2005.
72. P. Prabhakaran, L. B. Ware, K. E. White, M. T. Cross, M. A. Matthay, M. A. Olman, "Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 285, no. 1, pp. L20-L28, 2003.
73. L. B. Ware, X. Fang, M. A. Matthay, "Protein C and thrombomodulin in human acute lung injury," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 285, no. 3, pp. L514-L521, 2003.
74. A. Sapru, C. S. Calfee, K. D. Liu et al., "Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome," Intensive Care Medicine, vol. 41, pp. 470-478, 2015.
75. A.Koutsi,A. Papapanagiotou,A.G. Papavassiliou, "Thrombomodulin: from haemostasis to inflammation and tumourigenesis," International Journal of Biochemistry and Cell Biology, vol. 40, no. 9, pp. 1669-1673, 2008.
76. E.M.Conway, "Thrombomodulin and its role in inflammation," Seminars in Immunopathology, vol. 34, no. 1, pp. 107-125, 2012.
77. W. Ruf and M. Riewald, "Tissue factor-dependent coagulation protease signaling in acute lung injury," Critical Care Medicine, vol. 31, no. 4, pp. S231-S237, 2003.
78. M.Xue, Z. Sun, M. Shao et al., "Diagnostic and prognostic utility of tissue factor for severe sepsis and sepsis-induced acute lung injury," Journal of Translational Medicine, vol. 13, article 172, 2015.
79. J. A. Bastarache, S. C. Sebag, J. K. Clune et al., "Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress," Thorax, vol. 67, no. 12, pp. 1032-1039, 2012.
80. S. Mumby, L. Ramakrishnan, T. W. Evans, M. J. D. Griffiths, G. J. Quinlan, "Methemoglobin-induced signaling and chemokine responses in human alveolar epithelial cells," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 306, no. 1, pp. L88-L100, 2014.
81. A. Fein, R. F. Grossman, J. G. Jones et al., "The value of edema fluid protein measurement in patients with pulmonary edema," The American Journal ofMedicine, vol. 67, no. 1, pp. 32-38, 1979.
82. L. B. Ware, R. D. Fremont, J. A. Bastarache, C. S. Calfee, M. A. Matthay, "Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma protein ratio," European Respiratory Journal, vol. 35, no. 2, pp. 331-337, 2010.
83. D. R.Thickett, L. Armstrong, S. J. Christie, A. B. Millar, "Vascular endothelial growth factormay contribute to increased vascular permeability in acute respiratory distress syndrome," American Journal of Respiratory and Critical CareMedicine, vol. 164, no. 9, pp. 1601-1605, 2001.
84. Y. Abadie, F. Bregeon, L. Papazian et al., "Decreased VEGF concentration in lung tissue and vascular injury during ARDS," European Respiratory Journal, vol. 25, no. 1, pp. 139-146, 2005.
85. T. J. Desai andW. V. Cardoso, "Growth factors in lung development and disease: friends or foe" Respiratory Research, vol. 3, article 2, 2002.
86. B.Maitre, S. Boussat, D. Jean et al., "Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury," European Respiratory Journal, vol. 18,no. 1, pp. 100-106, 2001.
87. Z. Borok, S. I. Danto, L. L. Dimen, X.-L. Zhang, R. L. Lubman, "Na+-K+-ATPase expression in alveolar epithelial cells: upregulation of active ion transport by KGF," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 274, no. 1, pp. L149-L158, 1998.
88. L. B. Ware and M. A. Matthay, "Keratinocyte and hepatocyte growth factors in the lung: Roles in lung development, inflammation, repair,"The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 282, no. 5, pp. L924-L940, 2002.
89. V. Galani, E. Tatsaki, M. Bai et al., "The role of apoptosis in the pathophysiology of Acute Respiratory Distress Syndrome (ARDS): an up-to-date cell-specific review," Pathology Research and Practice, vol. 206, no. 3, pp. 145-150, 2010.
90. R.C. Pires-Neto, M. M. B. Morales, T. Lancas et al., "Expression of acute-phase cytokines, surfactant proteins, epithelial apoptosis in small airways of human acute respiratory distress syndrome," Journal of Critical Care, vol. 28, no. 1, pp. 111.e9-111.e15, 2013.
91. D. Talmor, T. Sarge, A. Legedza et al., "Cytokine release following recruitment maneuvers," Chest, vol. 132, no. 5, pp. 1434-1439, 2007.
92. J. M. Walter, J. Wilson, L. B. Ware, "Biomarkers in acute respiratory distress syndrome: from pathobiology to improving patient care," Expert Review of Respiratory Medicine, vol. 8, no. 5, pp. 573-586, 2014.
93. C. S. Calfee, K. Delucchi, P. E. Parsons, B. T. Thompson, L. B. Ware, M. A. Matthay, "Latent class models identify two subphenotypes in respiratory distress syndrome with differential response to positive end-expiratory pressure," Annals of the American Thoracic Society, vol. 12, supplement 1, p. S77, 2015.
94. V. Newman, R. F. Gonzalez, M. A.Matthay, L. G. Dobbs, "A novel alveolar type I cell-specific biochemical marker of human acute lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 3, pp. 990-995, 2000.
95. A. M. Schmidt, S.D.Yan, S. F.Yan,D.M. Stern, "Thebiology of the receptor for advanced glycation end products and its ligands," Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1498, no. 2-3, pp. 99-111, 2000.
96. T. Uchida, M. Shirasawa, L. B. Ware et al., "Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 9, pp. 1008-1015, 2006.
97. M. T.Kuipers, T. van der Poll, M. J. Schultz,C.W.Wieland, "Bench-to-bedside review: damage-associated molecular patterns in the onset of ventilator-induced lung injury," Critical Care, vol. 15, no. 6, article 235, 2011.
98. T. Uchida, M. Shirasawa, L. B. Ware et al., "Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 9, pp. 1008-1015, 2006.
99. C. S. Calfee, L. B.Ware, M. D. Eisner et al., "Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury," Thorax, vol. 63, no. 12, pp. 1083-1089, 2008.
100. M. Jabaudon, E. Futier, L. Roszyk et al., "Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients," Critical Care Medicine, vol. 39, no. 3, pp. 480-488, 2011.
101. M. Jabaudon, R. Blondonnet, L. Roszyk et al., "Soluble RAGE predicts impaired alveolar fluid clearance in acute respiratory distress syndrome,"AmericanJournal of Respiratory andCritical Care Medicine, vol. 192, no. 2, 2015.
102. M. D. Johnson, J. H. Widdicombe, L. Allen, P. Barbry, L. G. Dobbs, "Alveolar epithelial I cells contain transport proteins and transport sodium, supporting an active role for type I cells in regulation of lung liquid homeostasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 4, pp. 1966-1971, 2002.
103. L. E. Hanford, J. J. Enghild, Z. Valnickova et al., "Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)," The Journal of Biological Chemistry, vol. 279, no. 48, pp. 50019-50024, 2004.
104. C. Cheng, K. Tsuneyama, R. Kominami et al., "Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs," Modern Pathology, vol. 18, no. 10, pp. 1385-1396, 2005.
105. J. Brett, A. M. Schmidt, S. D. Yan et al., "Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues," The American Journal of Pathology, vol. 143, no. 6, pp. 1699-1712, 1993.
106. L. E. Hanford, C. L. Fattman, L. M. Schaefer, J. J. Enghild, Z. Valnickova, T. D. Oury, "Regulation of receptor for advanced glycation end products during bleomycin-induced lung injury," American Journal of Respiratory Cell andMolecular Biology, vol. 29, no. 3, pp. S77-S81, 2003.
107. J. M. Englert, L. E. Hanford, N. Kaminski et al., "A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis,"TheAmerican Journal of Pathology, vol. 172, no. 3, pp. 583-591, 2008.
108. A. M. Schmidt, S. D. Yan, S. F. Yan, D. M. Stern, "The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses," The Journal of Clinical Investigation, vol. 108, no. 7, pp. 949-955, 2001.
109. M. Jabaudon, R. Blondonnet, L. Roszyk et al., "Soluble forms and ligands of the receptor for advanced glycation end-products in patients with acute respiratory distress syndrome: an observational prospective study," PLoS ONE, vol. 10, no. 8, Article ID e0135857, 2015.
110. C. A. Downs, L. H. Kreiner, N. M. Johnson, L. A. Brown, M. N. Helms, "Receptor for advanced glycation end-products regulates lung fluid balance via protein kinase C-gp91phox signaling to epithelial sodium channels," American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 1, pp. 75-87, 2015.
111. R. Briot, J. A. Frank, T. Uchida, J.W. Lee, C. S. Calfee, M. A. Matthay, "Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type i cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs," Chest, vol. 135, no. 2, pp. 269-275, 2009.
112. J.-M. Constantin, "Impact of Inflammation Biomarkers on the Acute Respiratory Distress Syndrome (ARDS) Definition," (NCT01161901), https://clinicaltrials.gov/ct2/show/NCT01161901term=constantin+clermont&rank=5.
113. M. Jabaudon,N.Hamroun, L. Roszyk et al., "Effects of a recruitment maneuver on plasma levels of soluble RAGE in patients with diffuse acute respiratory distress syndrome: a prospective randomized crossover study," Intensive Care Medicine, vol. 41, no. 5, pp. 846-855, 2015.
114. M. Jabaudon, "PredictiveValues of Plasma SolubleRAGE Levels and RAGE Polymorphisms for the Onset of Acute Respiratory Distress Syndrome in Critically Ill Patients (PrediRAGE Study)," in: ClinicalTrials.gov, 2014, http://clinicaltrials.gov/show/NCT02070536.
115. J. Bhattacharya and M. A.Matthay, "Regulation and repair of the alveolar-capillary barrier in acute lung injury," Annual Review of Physiology, vol. 75, pp. 593-615, 2013.
116. I. Frerking, A. Günther, W. Seeger, U. Pison, "Pulmonary surfactant: functions, abnormalities and therapeutic options," Intensive Care Medicine, vol. 27, no. 11, pp. 1699-1717, 2001.
117. D. G. Ashbaugh, D. B. Bigelow, T. L. Petty, B. E. Levine, "Acute respiratory distress in adults," The Lancet, vol. 2, no. 7511, pp. 319-323, 1967.
118. I. R. Doyle, A. D. Bersten, T. E. Nicholas, "Surfactant proteins-A and-B are elevated in plasma of patients with acute respiratory failure," American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 4, pp. 1217-1229, 1997.
119. K. E. Greene, S. Ye, R. J. Mason, P. E. Parsons, "Serum surfactant protein-A levels predict development of ARDS in atrisk patients," Chest, vol. 116, supplement 1, pp. 90S-91S, 1999.
120. A. D. Bersten, T. Hunt, T. E. Nicholas, I. R. Doyle, "Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 4, pp. 648-652, 2001.
121. A. Ishizaka, T.Matsuda, K. H. Albertine et al., "Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 286, no. 6, pp. L1088-L1094, 2004.
122. N.Nathani, G.D. Perkins,W. Tunnicliffe,N.Murphy, M.Manji,D. R.Thickett, "Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome," Critical Care, vol. 12, article R12, 2008.
123. T. Kondo, N. Hattori, N. Ishikawa et al., "KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome," Respiratory Research, vol. 12, article 32, 2011.
124. R. Lucas,A.D.Verin,S.M.Black, J.D. Catravas, "Regulators of endothelial and epithelial barrier integrity and function in acute lung injury," Biochemical Pharmacology, vol. 77, no. 12, pp. 1763-1772, 2009.
125. A. Binnie, J. L. Tsang, C. C. dos Santos, "Biomarkers in acute respiratory distress syndrome," Current Opinion in Critical Care, vol. 20, no. 1, pp. 47-55, 2014.
126. S. Tsigkos, M. Koutsilieris,A. Papapetropoulos, "Angiopoietins in angiogenesis and beyond," Expert Opinion on Investigational Drugs, vol. 12, no. 6, pp. 933-941, 2003.
127. U. Fiedler, Y. Reiss, M. Scharpfenecker et al., "Angiopoietin-2 sensitizes endothelial cells to TNF-and has a crucial role in the induction of inflammation," Nature Medicine, vol. 12, no. 2, pp. 235-239, 2006.
128. V. Bhandari and J. A. Elias, "The role of angiopoietin 2 in hyperoxia-induced acute lung injury," Cell Cycle, vol. 6, no. 9, pp. 1049-1052, 2007.
129. N. J. Meyer, M. Li, R. Feng et al., "ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio," American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 10, pp. 1344-1353, 2011.
130. A. Agrawal, M. A. Matthay, K. N. Kangelaris et al., "Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients," American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 7, pp. 736-742, 2013.
131. T. Wada, S. Jesmin, S. Gando et al., "The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness," Journal of Inflammation, vol. 10, article 6, 2013.
132. T. Ong, D. E. McClintock, R. H. Kallet, L. B. Ware, M. A. Matthay, K. D. Liu, "Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients," Critical Care Medicine, vol. 38, no. 9, pp. 1845-1851, 2010.
133. K. A. Roebuck and A. Finnegan, "Regulation of intercellular adhesion molecule-1 (CD54) gene expression," Journal of Leukocyte Biology, vol. 66, no. 6, pp. 876-888, 1999.
134. E. R. Conner, L. B. Ware, G. Modin, M. A. Matthay, "Elevated pulmonary edema fluid concentrations of soluble intercellular adhesion molecule-1 in patients with acute lung injury: biological and clinical significance," Chest, vol. 116, pp. 83S-84S, 1999.
135. C. S. Calfee, M. D. Eisner, P. E. Parsons et al., "Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury," Intensive Care Medicine, vol. 35, no. 2, pp. 248-257, 2009.
136. P. Agouridakis, D. Kyriakou, M. G. Alexandrakis et al., "The predictive role of serum and bronchoalveolar lavage cytokines and adhesionmolecules for acute respiratory distress syndrome development and outcome," Respiratory Research, vol. 3, article 25, 2002.
137. H. R. Flori, L. B. Ware, D. Glidden, M. A. Matthay, "Early elevation of plasma soluble intercellular adhesionmolecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation," Pediatric Critical Care Medicine, vol. 4, no. 3, pp. 315-321, 2003.
138. A. Sousa, F. Raposo, S. Fonseca et al., "Measurement of cytokines and adhesion molecules in the first 72 hours after severe trauma: association with severity and outcome," Disease Markers, vol. 2015,Article ID 747036, 8 pages, 2015.
139. S. Gando, T. Kameue, N. Matsuda et al., "Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma," Thrombosis and Haemostasis, vol. 88, no. 6, pp. 943-949, 2002.
140. K. Xing, S.Murthy,W. C. Liles, J. M. Singh, "Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review," Critical Care, vol. 16, article R7, 2012.
141. J. Boldt, M. Wollbrück, D. Kuhn, L. C. Linke, G. Hempelmann, "Do plasma levels of circulating soluble adhesion molecules differ between surviving and nonsurviving critically ill patients" Chest, vol. 107, no. 3, pp. 787-792, 1995.
142. F. Sakamaki, A. Ishizaka, M. Handa et al., "Soluble form of Pselectin in plasma is elevated in acute lung injury," American Journal of Respiratory and Critical CareMedicine, vol. 151, no. 6, pp. 1821-1826, 1995.
143. E. L. Burnham,M.Moss,F.Harris,L. A. S. Brown, "Elevated plasma and lung endothelial selectin levels in patients with acute respiratory distress syndrome and a history of chronic alcohol abuse," Critical Care Medicine, vol. 32, no. 3, pp. 675-679, 2004.
144. K.Okajima,N.Harada,G. Sakurai et al., "Rapid assay for plasma soluble E-selectin predicts the development of acute respiratory distress syndrome in patients with systemic inflammatory response syndrome," Translational Research, vol. 148, no. 6, pp. 295-300, 2006.
145. A. R. L. Medford andA. B. Millar, "Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm" Thorax, vol. 61, no. 7, pp. 621-626, 2006.
146. M. Shibuya, "Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis," Journal of Biochemistry and Molecular Biology, vol. 39, no. 5, pp. 469-478, 2006.
147. R. J. Kaner, J. V. Ladetto, R. Singh, N. Fukuda,M. A.Matthay, R. G. Crystal, "Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema," American Journal of Respiratory Cell andMolecular Biology, vol. 22, no. 6, pp. 657-664, 2000.
148. L. Azamfirei, S. Gurzu, R. Solomon et al., "Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome," Minerva Anestesiologica, vol. 76, no. 8, pp. 609-616, 2010.
149. D. R. Thickett, L. Armstrong, A. B. Millar, "A role for vascular endothelial growth factor in acute and resolving lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 10, pp. 1332-1337, 2002.
150. A. C. A. Carvalho, S.M. Bellman, V. J. Saullo, D. Quinn,W. M. Zapol, "Altered factor VIII in acute respiratory failure," The New England Journal of Medicine, vol. 307, no. 18, pp. 1113-1119, 1982.
151. D. B. Rubin, J. P. Wiener-Kronish, J. F. Murray et al., "Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome," Journal of Clinical Investigation, vol. 86, no. 2, pp. 474-480, 1990.
152. M. Moss, L. Ackerson, M. K. Gillespie, F. A. Moore, E. E. Moore, P. E. Parsons, "Von willebrand factor antigen levels are not predictive for the adult respiratory distress syndrome," American Journal of Respiratory and Critical CareMedicine, vol. 151, no. 1, pp. 15-20, 1995.
153. A. K. Sabharwal, S. P. Bajaj, A. Ameri et al., "Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis," American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 3 I, pp. 758-767, 1995.
154. P. R. M. Rocco, C. Dos Santos, P. Pelosi, "Lung parenchyma remodeling in acute respiratory distress syndrome," Minerva Anestesiologica, vol. 75, no. 12, pp. 730-740, 2009.
155. B. C. Starcher, "Lung elastin and matrix," Chest, vol. 117, no. 5, supplement 1, pp. 229S-234S, 2000.
156. G. M. Albaiceta, A.Gutierrez-Fernández, E. Garcá-Prieto et al., "Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury,"American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 5, pp. 555-563, 2010.
157. S. E. G. Fligiel, T. Standiford, H. M. Fligiel et al., "Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury," Human Pathology, vol. 37, no. 4, pp. 422-430, 2006.
158. M. Y. F. Kong, Y. Li, R. Oster, A. Gaggar, J. P. Clancy, "Early elevation of matrix metalloproteinase-8 and-9 in pediatric ARDS is associated with an increased risk of prolonged mechanical ventilation," PLoS ONE, vol. 6, no. 8, Article ID e22596, 2011.
159. A. González-López and G. M. Albaiceta, "Repair after acute lung injury: molecular mechanisms and therapeutic opportunities," Critical Care, vol. 16, no. 2, article 209, 2012.
160. M. Bhatia and S. Moochhala, "Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome," Journal of Pathology, vol. 202, no. 2, pp. 145-156, 2004.
161. L. A. Dada and J. I. Sznajder, "Hypoxic inhibition of alveolar fluid reabsorption," in Hypoxia and the Circulation, pp. 159-168, Springer US, 2007.
162. A. E. Postlethwaite and J. M. Seyer, "Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor (TNF-) and a synthetic TNF-31-68 peptide," The Journal of Experimental Medicine, vol. 172, no. 6, pp. 1749-1756, 1990.
163. P. F. Piguet, M. A. Collart, G. E. Grau, A.-P. Sappino, P. Vassalli, "Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis," Nature, vol. 344, no.6263, pp. 245-247, 1990.
164. W. Y. Park, R. B. Goodman, K. P. Steinberg et al., "Cytokine balance in the lungs of patients with acute respiratory distress syndrome," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, pp. 1896-1903, 2001.
165. J. Pugin, B. Ricou, K. P. Steinberg, P. M. Suter, T. R.Martin, "Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1," American Journal of Respiratory and Critical CareMedicine, vol. 153, no. 6, pp. 1850-1856, 1996.
166. G. U. Meduri, G. Kohler, S. Headley, E. Tolley, F. Stentz, A. Postlethwaite, "Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome," Chest, vol. 108, no. 5, pp. 1303-1314, 1995.
167. R. Roten,M.Markert, F. Feihl,M.-D. Schaller,M.-C.Tagan, C. Perret, "Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome," American Review of Respiratory Disease, vol. 143, no. 3, pp. 590-592, 1991.
168. T. Dolinay, Y. S. Kim, J. Howrylak et al., "Inflammasomeregulated cytokines are critical mediators of acute lung injury," American Journal of Respiratory and Critical CareMedicine, vol. 185, no. 11, pp. 1225-1234, 2012.
169. D. McClintock, H. Zhuo, N. Wickersham, M. A. Matthay, L. B. Ware, "Biomarkers of inflammation, coagulation and fibrinolysis predictmortality in acute lung injury," Critical Care, vol. 12, no. 2, article R41, 2008.
170. R. P. Baughman, K. L. Gunther, M. C. Rashkin, D. A. Keeton, E. N. Pattishall, "Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators," American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 1, pp. 76-81, 1996.
171. H. Schütte, J. Lohmeyer, S. Rosseau et al., "Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema," European Respiratory Journal, vol. 9, no. 9, pp. 1858-1867, 1996.
172. A. Kurdowska, E. J. Miller, J. M. Noble et al., "Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome," The Journal of Immunology, vol. 157, no. 6, pp. 2699-2706, 1996.
173. A. Kurdowska, J. M. Noble, I. S. Grant, C. R. Robertson, C. Haslett, S. C. Donnelly, "Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome," Critical Care Medicine, vol. 30, no. 10, pp. 2335-2337, 2002.
174. A. Krupa, H. Kato, M. A. Matthay, A. K. Kurdowska, "Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury,"The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 286, no. 6, pp. L1105-L1113, 2004.
175. R. Fudala, A. Krupa, M. A. Matthay, T. C. Allen, A. K. Kurdowska, "Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 293, no. 2, pp. L364-L374, 2007.
176. M. A. Matthay and L. B. Ware, "Resolution of alveolar edema in acute respiratory distress syndrome. Physiology and biology," American Journal of Respiratory and Critical CareMedicine, vol. 192, no. 2, pp. 124-125, 2015.
177. P. Ralph, I. Nakoinz, A. Sampson-Johannes et al., "IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor," The Journal of Immunology, vol. 148, no. 3, pp. 808-814, 1992.
178. M. Seitz, P. Loetscher, B. Dewald, H. Towbin, H. Gallati, M. Baggiolini, "Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts," European Journal of Immunology, vol. 25, no. 4, pp. 1129-1132, 1995.
179. C.-J.Lo,M. Fu,H. G. Cryer, "Interleukin 10 inhibits alveolar macrophage production of inflammatory mediators involved in adult respiratory distress syndrome," Journal of Surgical Research, vol. 79, no. 2, pp. 179-184, 1998.
180. A. Sapru, J. L. Wiemels, J. S. Witte, L. B. Ware, M. A. Matthay, "Acute lung injury and the coagulation pathway: potential role of gene polymorphisms in the protein C and fibrinolytic pathways," IntensiveCareMedicine, vol. 32,no. 9, pp. 1293-1303, 2006.
181. V. Jalkanen, R. Yang, R. Linko et al., "SuPAR and PAI-1 in critically ill, mechanically ventilated patients," Intensive Care Medicine, vol. 39, no. 3, pp. 489-496, 2013.
182. L. B.Ware, M. A.Matthay, P. E. Parsons et al., "Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome," Critical Care Medicine, vol. 35, no. 8, pp. 1821-1828, 2007.
183. C. T. Esmon, "Inflammation and the activated protein C anticoagulant pathway," Seminars in Thrombosis and Hemostasis, vol. 32, supplement 1, pp. 49-60, 2006.
184. M. F. Nold, C. A. Nold-Petry, D. Fischer et al., "Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock,"Thrombosis andHaemostasis, vol. 98,no. 5, pp. 1118-1126, 2007.
185. T. Cheng, D. Liu, J. H. Griffin et al., "Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective," Nature Medicine, vol. 9, no. 3, pp. 338-342, 2003.
186. S. C. Christiaans, B. M. Wagener, C. T. Esmon, J. F. Pittet, "Protein C and acute inflammation: a clinical and biological perspective,"TheAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 305, no. 7, pp. L455-L466, 2013.
187. J. A. Bastarache, L.Wang, T. Geiser et al., "The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor," Thorax, vol. 62, no. 7, pp. 608-616, 2007.
188. A. J.Ghio, J. H. Richards,K.M.Crissman,J.D.Carter, "Iron disequilibrium in the rat lung after instilled blood," Chest, vol. 118, no. 3, pp. 814-823, 2000.
189. J. A. Bastarache, J. L. Wynn, L. B. Ware, "Fanning the fire: can methemoglobin enhance neutrophil activation" EBioMedicine, vol. 2, no. 3, pp. 184-185, 2015.
190. E. L. Burnham, W. J. Janssen, D. W. H. Riches, M. Moss, G. P. Downey, "The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance," European Respiratory Journal, vol. 43, no. 1, pp. 276-285, 2014.
191. T. Geiser, K. Atabai, P.-H. Jarreau, L. B. Ware, J. Pugin, M. A. Matthay, "Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1-dependent mechanism,"American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 6, pp. 1384-1388, 2001.
192. K. Atabai,M. Ishigaki,T.Geiser, I.Ueki,M.A.Matthay,L. B. Ware, "Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 283, no. 1, pp. L163-L169, 2002.
193. M. Mura, C. C. dos Santos, D. Stewart, M. Liu, "Vascular endothelial growth factor and related molecules in acute lung injury," Journal of Applied Physiology, vol. 97, no. 5, pp. 1605-1617, 2004.
194. C. Quesnel, S. Marchand-Adam, A. Fabre et al., "Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 294, no. 2, pp. L334-L343, 2008.
195. S. Fan, Y. X. Ma, J.-A. Wang et al., "The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3 kinase," Oncogene, vol. 19, no. 18, pp. 2212-2223, 2000.
196. J.-B. Stern, L. Fierobe, C. Paugam et al., "Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients," Critical Care Medicine, vol. 28, no. 7, pp. 2326-2333, 2000.
197. G. M. Verghese, K. McCormick-Shannon, R. J. Mason, M. A.Matthay, "Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury: biologic and clinical significance," American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 2, pp. 386-394, 1998.
198. M. A. Rahman, K. Sundaram, S. Mitra, M. A. Gavrilin, M. D. Wewers, "Receptor interacting protein-2 plays a critical role in human lung epithelial cells survival in response to Fasinduced cell-death," PLoS ONE, vol. 9, no. 3, Article ID e92731, 2014.
199. A. D. Lopez, S. Avasarala, S. Grewal, A. K. Murali, L. London, "Differential role of the Fas/Fas ligand apoptotic pathway in inflammation and lung fibrosis associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia and acute respiratory distress syndrome," The Journal of Immunology, vol. 183, no. 12, pp. 8244-8257, 2009.
200. G. Matute-Bello, W. C. Liles, K. P. Steinberg et al., "Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS)," Journal of Immunology, vol. 163, no. 4, pp. 2217-2225, 1999.
201. M. Tanaka, T. Suda, T. Takahashi, S. Nagata, "Expression of the functional soluble form of human Fas ligand in activated lymphocytes," The EMBO Journal, vol. 14, no. 6, pp. 1129-1135, 1995.
202. K. H. Albertine, M. F. Soulier, Z.Wang et al., "Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome,"TheAmerican Journal of Pathology, vol. 161, no. 5,pp. 1783-1796, 2002.
203. J. Farjanel, D. J. Hartmann, B. Guidet, L. Luquel, G. Offenstadt, "Four markers of collagen metabolism as possible indicators of disease in the adult respiratory distress syndrome," American Review of Respiratory Disease, vol. 147, no. 5, pp. 1091-1099, 1993.
204. A. N. Chesnutt,M. A.Matthay, F. A. Tibayan, J. G. Clark, "Early detection of type iii procollagen peptide in acute lung injury: pathogenetic and prognostic significance," American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 3, pp. 840-845, 1997.
205. J. G. Clark, J. A. Milberg, K. P. Steinberg, L. D. Hudson, "Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death," Annals of Internal Medicine, vol. 122, no. 1, pp. 17-23, 1995.
206. J.-M. Forel, C. Guervilly, S. Hraiech et al., "Type III procollagen is a reliablemarker of ARDS-associated lung fibroproliferation," Intensive Care Medicine, vol. 41, no. 1, pp. 1-11, 2015.
207. C. M. Hendrickson, B. Crestani, M. A. Matthay, "Biology and pathology of fibroproliferation following the acute respiratory distress syndrome," Intensive Care Medicine, vol. 41, no. 1, pp. 147-150, 2015.
208. L. B. Ware, T. Koyama, D. D. Billheimer et al., "Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury," Chest, vol. 137, no. 2, pp. 288-296, 2010.
209. J.-M. Constantin and E. Futier, "Lung imaging in patients with acute respiratory distress syndrome: from an understanding of pathophysiology to bedside monitoring,"Minerva Anestesiologica, vol. 79, no. 2, pp. 176-184, 2013.
210. L. Puybasset, P. Gusman, J.-C. Muller, P. Cluzel, P. Coriat, J.-J. Rouby, "Regional distribution of gas and tissue in acute respiratory distress syndrome. III. Consequences for the effects of positive end-expiratory pressure," Intensive Care Medicine, vol. 26, no. 9, pp. 1215-1227, 2000.
211. J.-M. Constantin, S. Jaber, E. Futier et al., "Respiratory effects of different recruitment maneuvers in acute respiratory distress syndrome," Critical Care, vol. 12, article R50, 2008.
212. J.-M. Constantin, S. Cayot-Constantin, L. Roszyk et al., "Response to recruitment maneuver influences net alveolar fluid clearance in acute respiratory distress syndrome," Anesthesiology, vol. 106, no. 5, pp. 944-951, 2007.
213. R. Mayeux, "Biomarkers: potential uses and limitations," NeuroRx, vol. 1, no. 2, pp. 182-188, 2004.
214. V. G. De Gruttola, P. Clax, D. L. DeMets et al., "Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop," Controlled Clinical Trials, vol. 22, no. 5, pp. 485-502, 2001.
215. P. Ray, Y. L. Manach, B. Riou, T. T. Houle, "Statistical evaluation of a biomarker," Anesthesiology, vol. 112, no. 4, pp. 1023-1040, 2010.
216. H. Gerlach and S. Toussaint, "Sensitive, specific, predictive. . . statistical basics: how to use biomarkers," Critical Care Clinics, vol. 27, no. 2, pp. 215-227, 2011.
217. M. Bhargava and C. H. Wendt, "Biomarkers in acute lung injury," Translational Research, vol. 159, no. 4, pp. 205-217, 2012.